A Randomized, double-blind, placebo controlled, phase III scientific trial evaluated the efficacy and basic safety profile of adalimumab for a monotherapy in individuals with RA who experienced unsuccessful to respond to csDMARDs [191]. The results confirmed each statistically major enhancement during the illness action and a great basic safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/